Zofran and Primary myelofibrosis - a phase IV clinical study of FDA data

Summary:

Primary myelofibrosis is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Jakafi, and have Myelodysplastic syndrome.

The phase IV clinical study analyzes which people have Primary myelofibrosis when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Primary myelofibrosis?

Primary myelofibrosis (primary disorder of the bone marrow) is found to be associated with 324 drugs and 840 conditions by eHealthMe. Check the latest studies of Primary myelofibrosis.

On Apr, 25, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 33 people (0.04%) have Primary myelofibrosis.

Could Zofran cause Primary myelofibrosis?

Among these 33 people:

How long have people been on Zofran when they have Primary myelofibrosis? *

What is the gender of people who have Primary myelofibrosis when taking Zofran? *

female: 41.38 %
male: 58.62 %

What is the age of people who have Primary myelofibrosis when taking Zofran? *

What are other drugs people take besides Zofran? *

What are other side effects people have besides Primary myelofibrosis? *

Weakness: 9 people, 27.27%
Anaemia (lack of blood): 8 people, 24.24%
Hepatomegaly (abnormal enlargement of the liver): 8 people, 24.24%
Thrombocytopenia (decrease of platelets in blood): 8 people, 24.24%
Dyspnea (difficult or laboured breathing): 7 people, 21.21%
Fatigue (feeling of tiredness): 7 people, 21.21%
Weight Decreased: 5 people, 15.15%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 5 people, 15.15%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 15.15%
Dyspnea Exertional: 5 people, 15.15%

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 5 people, 15.15%
Stress And Anxiety: 4 people, 12.12%
Oedema Peripheral (superficial swelling): 2 people, 6.06%
Diarrhea: 2 people, 6.06%
Iron Overload: 2 people, 6.06%
Kidney Infection (Pyelonephritis): 2 people, 6.06%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 2 people, 6.06%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 6.06%
Fever: 2 people, 6.06%
Ureteric Cancer: 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Primary myelofibrosis?

- Check whether Primary myelofibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Primary myelofibrosis:

Primary myelofibrosis (324 drugs)

Browse all the conditions that are associated with Primary myelofibrosis:

Primary myelofibrosis (840 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.